Research Desk Line-up: Biogen Post Earnings Coverage

LONDON, UK / ACCESSWIRE / July 27, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Nivalis Therapeutics, Inc. (NASDAQ: NVLS) ("Nivalis"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=NVLS. Alpine Immune Sciences, Inc. ("Alpine") announced on July 24, 2017, the completion of the transaction, where it announced to acquire a wholly-owned subsidiary of Nivalis Therapeutics in an all-stock transaction on April 18, 2017. Under terms of the merger, Nivalis and Alpine would join to be a combined Company with a novel protein-based discovery platform, focused on inflammation and immuno-oncology. Alpine announced that from July 25, 2017, it would be trading on the NASDAQ national market under the ticker, "ALPN". For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Biogen Inc. (NASDAQ: BIIB) for due-diligence and potential coverage as the Company reported on July 25, 2017, its financial results for Q2 2017. Tune into our site to register for a free membership, and be among the early birds that get our report on Biogen when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on NVLS; also brushing on BIIB. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=NVLS

http://protraderdaily.com/optin/?symbol=BIIB

The Announcement

Nivalis views this transaction as a step to advance new therapies for patients and to generate significant value for its shareholders. Alpine, according to the Company, has discovered novel ways to target the immune synapse, and the Company which is led by a solid management team brought immunotherapeutics to the market. According to Alpine, the merger offers the Company the opportunity to accelerate the development of its novel immunotherapy platform focused on both inflammation and immuno-oncology.

The Proposed Merger

This agreement follows the January 03, 2017, announcement where Nivalis initiated a process to explore and review a range of strategic alternatives. As a part of the announcement, bids were solicited, and later Nivalis' Board of Directors unanimously decided to approve and enter into a definitive merger agreement with Alpine. Alpine received an additional $17 million from Frazier Healthcare Partners, Alpine BioVentures, and OrbiMed Advisors, prior to the close of the transaction.

Nivalis Therapeutics developed a portfolio of novel disease modifying therapies designed to preserve intracellular GSNO levels. GSNO, or S-nitroso-glutathione, is a molecule with cell signaling effects which is implicated in the pathophysiology of cystic fibrosis and other respiratory diseases. Post the execution of the transaction, Nivalis' shareholders will hold about 26% of the combined Company, while Alpine's shareholders will be entitled to 74% of the combined Company. Alpine stated that the exchange ratio was based on a valuation of Nivalis equal to $50 million, which included about $44 million in cash, expected to be held by Nivalis at the time of closing.

Company Growth Prospects

Alpine Immune Sciences, founded in 2015, has focused on the development of novel protein-based immunotherapies using its proprietary variant immunoglobin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets and includes many presents in the immune synapse. Alpine additionally developed its transmembrane immunomodulatory protein technology, based on its flagship platform to enhance engineered cell therapies.

The Company has also signed a worldwide research and license agreement with Kite Pharma, Inc., (NASDAQ: KITE) in October 2015, for up to $535 million in up front and potential milestone payments. In addition, the Kite Pharma agreement should also provide royalties on resulting sales.

Alpine is focused on the development of novel protein-based therapies using its variant immunoglobin domain platform technology. The Company plans to initiate a Phase-1 clinical trial with its first compound in H2 2018, which is a dual ICOS/CD28 antagonist engineered for use in autoimmune and inflammatory diseases.

Last Close Stock Review

On Monday, July 24, 2017, the stock closed the trading session flat at $9.60, with an average volume of 18.19 thousand shares. Nivalis Therapeutics' stock price surged 3.90% in the last one month, 14.29% in the past three months, and 11.11% in the previous six months. Furthermore, since the start of the year, shares of the Company have gained 7.14%. The stock currently has a market cap of $152.74 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily